The valuer general of Victoria has told the High Court that a property in Melbourne’s CBD should be valued at $6.2 million rather than $2.9 million, despite a heritage constraint on development.
Indian drug maker Cipla has lost a challenge to the extension of Novo Nordisk’s patent for Victoza, with a judge rejecting an argument that extensions can be granted only for active ingredients.
Maddocks has recruited a competition law specialist from Johnson Winter Slattery as a new partner in its corporate and commerical practice.
The federal government spent more than $600 million on private law firms in 2022-23, and Clayton Utz was the firm the government turned to the most.
As it fends off a suit by AstraZeneca seeking to block the sale of a cheaper version of Brilinta, generics maker Pharmacor claims a patent for the heart attack drug should not have been extended.
Logistics giant Qube has partially prevailed in setting aside amounts Martinus Rail claimed it was owed under a contract for work at an intermodal freight terminal in Moorebank, NSW.
The corporate watchdog is suing the second Big Four bank in two months, alleging NAB mishandled hundreds of hardship applications from vulnerable customers.
Rugby Australia is considering an insolvent trading cross-claim against the directors of the Melbourne Rebels, in a suit by the failed team which was cut from next year’s Super Rugby Pacific competition.
Cipla is opposing the extension of Novo Nordisk’s patent for its Victoza weight loss and diabetes drug, arguing extensions can only be granted for active ingredients and not entire formulations.
Holding Redlich has lost a veteran environment partner with extensive experience representing government clients and his team to Maddocks, marking the firm’s second lateral loss this week.